Valproic acid suppresses cervical cancer tumor progression possibly via activating Notch1 signaling and enhances receptor-targeted cancer chemotherapeutic via activating somatostatin receptor type II

Archives of Gynecology and Obstetrics

Volumn 288, Issue 2, 2013, Pages 393-400

  Tsai, Cheguo ^a   Leslie, Juliana S ^a   Franko Tobin, Laura G ^a   Prasnal, Monica C ^a   Yang, Tong ^b   Vienna Mackey, L ^a   Fuselier, Joseph A ^a   Coy, David H ^a   Liu, Mingqiu ^c   Yu, Changyuan ^d   Sun, Lichun ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c FUDAN UNIVERSITY   (China)

^d BEIJING UNIVERSITY OF CHEMICAL TECHNOLOGY   (China)

Author keywords

Cervical cancer; COL SST; Notch signaling; Receptor targeted; SSTR; Tumor; VPA

Indexed keywords

COLCHICINE DERIVATIVE; NERVE CELL ADHESION MOLECULE; NOTCH1 RECEPTOR; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR 2; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR SNAIL 1; TRANSCRIPTION FACTOR SNAIL 2; UNCLASSIFIED DRUG; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE ARREST; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME REGULATION; GENE SEQUENCE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR XENOGRAFT; UTERINE CERVIX CANCER;

ANIMALS; ANTICONVULSANTS; CARCINOMA; CELL DIFFERENTIATION; CELL PROLIFERATION; COLCHICINE; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLOOXYGENASE 2; DRUG COMBINATIONS; G2 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION; GENES, P53; HELA CELLS; HORMONES; HUMANS; MEMBRANE PROTEINS; MICE; MICE, NUDE; PHOSPHATIDYLINOSITOL 3-KINASES; PTEN PHOSPHOHYDROLASE; RECEPTOR, NOTCH1; RECEPTORS, SOMATOSTATIN; RNA, MESSENGER; SIGNAL TRANSDUCTION; SOMATOSTATIN; TUBULIN MODULATORS; VALPROIC ACID;

EID: 84880772752     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-013-2762-7     Document Type: Article

References (22)

1. Maillard I, Pear WS (2003) Notch and cancer: best to avoid the ups and downs. Cancer Cell 3:203-205
2. Dotto GP (2008) Notch tumor suppressor function. Oncogene 27:5115-5123
3. Koch U, Radtke F (2007) Notch and cancer: a double-edged sword. Cell Mol Life Sci 64:2746-2762
4. Talora C, Cialfi S, Segatto O (2005) Constitutively active Notch1 induces growth arrest of HPV-positive cervical cancer cells via separate signaling pathways. Exp Cell Res 305:343-354
5. Franko-Tobin LG, Mackey LV, Huang W (2011) Notch1-mediated tumor suppression in cervical cancer with the involvement of sst signaling and its application in enhanced SSTR-targeted therapeutics. Oncologist 17:220-232
6. Kostrouchová M, Kostrouch Z, Kostrouchová M (2007) Valproic acid, a molecular lead to multiple regulatory pathways. Folia Biol (Praha) 53:37-49
7. Platta CS, Greenblatt DY, Kunnimalaiyaan M (2008) Valproic acid induces Notch1 signaling in small cell lung cancer cells. J Surg Res 148:31-37
8. Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C (2008) Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev 34:206-222
9. Shabbeer S, Kortenhorst MS, Kachhap S, Galloway N, Rodriguez R, Carducci MA (2007) Multiple molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo. Prostate 67:1099-1110
10. Adler JT, Hottinger DG, Kunnimalaiyaan M (2010) Inhibition of growth in medullary thyroid cancer cells with histone deacetylase inhibitors and lithium chloride. J Surg Res 159:640-644
11. Sami S, Höti N, Xu HM, Shen Z, Huang X (2008) Valproic acid inhibits the growth of cervical cancer both in vitro and in vivo. J Biochem 144:357-362
12. Sun L, Coy DH (2011) Somatostatin receptor-targeted anti-cancer therapy. Cur Drug Deliv 8:2-10
13. Sun L, Luo J, Mackey VL (2007) Effects of camptothecin on tumor cell proliferation and angiogenesis when coupled to a bombesin analog used as a targeted delivery vector. Anticancer Drugs 18:341-348
14. Eastham AM, Spencer H, Soncin F (2007) Epithelial-mesenchymal transition events during human embryonic stem cell differentiation. Cancer Res 67:11254-11262
15. Kato Y, Yashiro M, Noda S (2010) Establishment and characterization of a new hypoxia-resistant cancer cell line, OCUM-12/Hypo, derived from a scirrhous gastric carcinoma. Br J Cancer 102:898-907
16. Forino M, Torregrossa R, Ceol M (2006) TGFb1 induces epithelial- mesenchymal transition, but not myofibroblast transdifferentiation of human kidney tubular epithelial cells in primary culture. Int J Exp Pathol 87:197-208
17. Lossi L, Gambino G, Ferrini F (2009) Posttranslational regulation of BCL2 levels in cerebellar granule cells: a mechanism of neuronal survival. Dev Neurobiol 69:855-870
18. Higashikawa K, Yoneda S, Tobiume K (2007) Snail-induced down-regulation of DeltaNp63alpha acquires invasive phenotype of human squamous cell carcinoma. Cancer Res 67:9207-9213
19. Gagnon V, Mathieu I, Sexton É (2004) AKT involvement in cisplatin chemoresistance of human uterine cancer cells. Gynecol Oncol 94:785-795
20. Georgeseu MM (2010) PTEN Tumor Suppressor Network in PI3K-Akt Pathway Control. Genes Cancer 1:1170-1177
21. Thiery JP (2002) Epithelial-mesenchymal transitions in tumor progression. Nat Rev Cancer 2:442-454
22. Reubi JC (2003) Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 24:389-427